1717 Langhorne Newtown Road
Suite 300
Langhorne, PA 19047
United States
(512) 614-1848
https://www.savarapharma.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 37
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Matthew Pauls J.D., M.B.A. | Chairman & CEO | 970k | S.O. | 1971 |
Mr. David L. Lowrance CPA | CFO, Chief Administrative Officer & Secretary | 667,4k | S.O. | 1968 |
Mr. Scott L. Wilhoit | Executive Vice President of Global Commercial | S.O. | S.O. | 1963 |
Dr. Brian Robinson M.D. | Senior VP of Global Medical Affairs | S.O. | S.O. | S.O. |
Dr. Yasmine Wasfi M.D., Ph.D. | Senior VP & Head of Clinical Development | S.O. | S.O. | S.O. |
Dr. Siddharth J. Advant Ph.D. | Executive Vice President of Global Technical Operations | S.O. | S.O. | S.O. |
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
L’ISS Governance QualityScore de Savara Inc. en date du 1 mai 2024 est 4. Les scores principaux sont Audit : 4; Société : 6; Droits des actionnaires : 1; Compensation : 7.